Aspray TJ, et al. - Researchers used dual-energy X-ray absorptiometry to determine the impact of vitamin D supplementation on bone mineral density (BMD) at the hip in 379 adults aged ≥ 70 years from the northeast of England who were randomized to 1 of 3 once-monthly doses of vitamin D₃ (12,000 IU, 24,000 IU, or 48,000 IU). The mean ± SD baseline plasma 25-hydroxyvitamin D (25[OH]D) concentration was 40.0 ± 20.1 nmol/L. Regarding the change in BMD over 12 months, the investigators observed no difference between the 3 doses of vitamin D, suggesting no impact of the intervention or a similar reduction of the anticipated decrease in BMD over 12 months. No dose-related adverse events were reported. Findings demonstrated the safety as well as the efficacy of the treatment in increasing plasma 25(OH)D concentrations among the participants. In all 3 groups, decreased levels of parathyroid hormone were noted, with a remarkably greater decrease observed in the 48,000-IU group vs the 12,000-IU group.